Tiziana Life Sciences (TLSA) announced that its investigational drug, intranasal foralumab, was featured on a prominent News Channel. The segment highlighted the experiences of the first patient dosed in the company’s expanded access program for moderate Alzheimer’s disease. In the segment, Joe and his Wife, Karen, shared their journey and shed light on the hope that innovative therapies like Foralumab offer for individuals battling moderate Alzheimer’s, a condition that currently has no cure and limited treatment options.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSA:
- Tiziana Life Sciences Faces Nasdaq Compliance Challenge
- Tiziana Life Sciences Reports Breakthrough in Spinal Cord Injury Treatment
- Tiziana will not engage in capital raising activities for ‘immediate future’
- Tiziana Life Sciences Unveils New Biomarkers in Treatment of Progressive Multiple Sclerosis
- Tiziana Life Sciences announces discovery of new immune biomarkers